New automated insulin delivery systems improve diabetes management: ADA

A new research highlights the significant benefits of advanced technological innovations in managing type 2 diabetes (T2D) was presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida. 3 studies here showed the positive impacts of automated insulin delivery (AID) systems and continuous glucose monitoring (CGM) on glycemic control and overall diabetes management.

With nearly 40 million Americans affected by diabetes and over 90% having T2D, the global prevalence of the disease continues to rise which makes the effective management strategies more critical than ever. The studies presented at the ADA Scientific Sessions emphasize the transformative potential of integrating advanced technologies into diabetes care for under-resourced populations.

These studies represent a significant advancement in diabetes management technologies which showed substantial improvements in glycemic control and quality of life for people with type 2 diabetes, highlighted the ADA chief scientific and medical officer. Leveraging this will help in empowering the patients with more effective and manageable treatment options, ultimately transforming the landscape of diabetes care.

The SECURE-T2D pivotal trial is the first large-scale, multicenter study which evaluated the Omnipod® 5 AID System that demonstrated significant benefits for adults with T2D. The Omnipod 5 AID System is a tubeless insulin pump that automatically adjusts insulin delivery based on CGM data to improve glycemic control by responding to glucose levels in real-time.

The trial included a total of 305 adults aged 18 to 75 with T2D after using various insulin regimens and with a baseline HbA1c of less than 12.0%. After a 14-day standard therapy phase to establish baseline glycemic control and the participants transitioned to 13 weeks of using the Omnipod 5 AID System. The primary endpoint was the change in HbA1c from baseline to 13 weeks. The study population was notably diverse, with 24% Black and 22% Hispanic/Latino participants.

The results showed a significant reduction in HbA1c levels from an average of 8.2% to 7.4% at the end of the study. The greatest improvements were noticed in participants with the highest baseline HbA1c. The results from the SECURE-T2D trial underline the potential of the Omnipod 5 AID System to transform diabetes management for adults with T2D.

Another study presented as, "Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes-Real-World Analysis," highlighted the significant impact of CGM on patients with T2D. The study evaluated the impact of CGM on adults who were using non-insulin therapies, basal insulin and prandial insulin. The 12-month retrospective analysis used data from a large claims database of over 7.1 million T2D patients and compared HbA1c levels before and after CGM use.

Among the 6,030 adults studied, significant HbA1c improvements were observed across all therapy groups after 12 months. These results suggest that CGM can play a crucial role in improving health outcomes for all diabetes patients, regardless of their treatment regimen. Also, the findings from a related late-breaking abstract revealed that CGM use in T2D results in more than a 50% reduction in all-cause hospitalizations and acute diabetes-related hospitalizations.

Another study presented during the general poster session demonstrated that CGM significantly improves glycemic control in adults with T2D who are not using insulin. The real-world study analyzed data from over 3,800 adults using Dexcom G6 and G7 sensors. The participants showed significant improvements after six months of CGM use with further progress at one year. The key findings included a 0.5% reduction in the glucose management indicator and a 17% increase in Time in Range (TIR). This study highlighted the advantages of the Dexcom High Alert feature, which notifies users when glucose levels exceed their selected targets. This encourages the significant long-term improvements in glycemic control observed in the study. Future research will continue to explore ongoing patterns of glycemic improvement and real-world behavior changes enabled by CGM, as well as the impact of other Dexcom system features on glycemic control.

Source:

Breakthrough studies on automated insulin delivery and CGM for type 2 diabetes unveiled at ADA scientific sessions. (n.d.). Diabetes.org. Retrieved June 26, 2024, from https://diabetes.org/newsroom/press-releases/breakthrough-studies-automated-insulin-delivery-and-cgm-type-2-diabetes